Cyproconazole


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D001836 Body Weight Changes PMID:27234313
MESH:D002972 Cleft Palate PMID:16781842
MESH:D006528 Carcinoma, Hepatocellular PMID:17557908
MESH:D006529 Hepatomegaly PMID:17557908; PMID:22334560; PMID:23721867; PMID:25182419; PMID:25656644; PMID:29038839
MESH:D006984 Hypertrophy PMID:22334560
MESH:D008113 Liver Neoplasms PMID:28058446
MESH:D008114 Liver Neoplasms, Experimental PMID:25656644
MESH:D009336 Necrosis PMID:25182419
MESH:D009422 Nervous System Diseases PMID:22045034
MESH:D011230 Precancerous Conditions PMID:25656644
MESH:D015431 Weight Loss PMID:27234313; PMID:30639745
MESH:D018248 Adenoma, Liver Cell PMID:17557908; PMID:25656644
MESH:D019465 Craniofacial Abnormalities PMID:32553615
MESH:D049188 Prenatal Injuries PMID:22664269
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:17557908; PMID:25656644; PMID:28058446

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.